1. Safety and Antiviral Activity of Albinterferon Alfa-2b Dosed Every Four Weeks in Genotype 2/3 Chronic Hepatitis C Patients 
Vincent G. Bain, Kelly D. Kaita, Paul Marotta, Eric M. Yoshida, Mark G. Swain, Robert J. Bailey, Keyur Patel, Patrick W. Cronin, Erik Pulkstenis, John G. McHutchison, G. Mani Subramanian 
Clinical Gastroenterology and Hepatology 
Volume 6, Issue 6, Pages (June 2008)
DOI: /j.cgh
Copyright © 2008 AGA Institute Terms and Conditions

2. Figure 1
Change in median ANCs and platelet counts (PLT) during the 24-week treatment duration and at weeks 4 and 12 of follow-up (FU) after completion of treatment. aP < .05.
Clinical Gastroenterology and Hepatology 2008 6, DOI: ( /j.cgh )
Copyright © 2008 AGA Institute Terms and Conditions

3. Figure 2 On-treatment antiviral response rates.
Clinical Gastroenterology and Hepatology 2008 6, DOI: ( /j.cgh )
Copyright © 2008 AGA Institute Terms and Conditions

4. Figure 3 SVR rates: overall and in genotypes (Gt) 2 and 3.
Clinical Gastroenterology and Hepatology 2008 6, DOI: ( /j.cgh )
Copyright © 2008 AGA Institute Terms and Conditions

5. Figure 4
Relation between SVR and baseline insulin resistance. Box-plot representation of HOMA-IR in patients with CHC who achieved SVR and those who failed to achieve SVR. aP = .002.
Clinical Gastroenterology and Hepatology 2008 6, DOI: ( /j.cgh )
Copyright © 2008 AGA Institute Terms and Conditions